Information non disponible
BCR-ABL1 transcript doubling time as a predictor for treatment-free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phaseArticle de revue
Br J Haematol, 196 (1), 2022.
Patient-reported fatigue refines prognosis in higher-risk myelodysplastic syndromes (MDS): a MDS-CAN studyArticle de revue
Br J Haematol, 194 (2), 2021.
Optimal duration of imatinib treatment/deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trialArticle de revue
Br J Haematol, 193 (4), 2021.
Risk of infection in MPN patients in the era of Covid-19: A prospective multicenter study of 257 patients from the CML-MPN Quebec Research GroupArticle de revue
Am J Hematol, 96 (6), 2021.
Revised 15-item MDS-specific frailty scale maintains prognostic potentialArticle de revue
Leukemia, 34 (12), 2020.
An MDS-specific frailty index based on cumulative deficits adds independent prognostic information to clinical prognostic scoringArticle de revue
Leukemia, 34 (5), 2020.
Molecular monitoring of therapeutic milestones and clinical outcomes in patients with chronic myeloid leukemiaArticle de revue
Cancer, 125 (4), 2019.
Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDSArticle de revue
Leuk Res, 74 , 2018.
Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysisArticle de revue
Br J Haematol, 179 (1), 2017.
A predictive model of response to erythropoietin stimulating agents in myelodysplastic syndrome: from the Canadian MDS patient registryArticle de revue
Ann Hematol, 96 (12), 2017.